<DOC>
	<DOCNO>NCT01144403</DOCNO>
	<brief_summary>This multicenter , open-label study ass efficacy safety MabThera ( rituximab ) add standard chemotherapy participant untreated Mantle Cell Lymphoma eligible autologous stem cell transplantation . Participants receive MabThera ( 372 mg/m^2 intravenously ) Day 1 28-day treatment cycle addition standard chemotherapy 6 cycle . In participant experience complete partial response , MabThera continue consolidation therapy 2 cycle .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Addition Regularly Prescribed Chemotherapy Patients With Untreated Mantle Cell Lymphoma .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>adult participant , &gt; /=18 year age untreated Mantle Cell Lymphoma , eligible Autologous Stem Cell Transplantation know mantle cell lymphoma international prognostic index ( MIPI ) diagnosis Eastern Cooperative Oncology Group ( ECOG ) performance status 02 adequate hematological , renal hepatic function know hypersensitivity murine proteins chemotherapy regimen previous firstline therapy history malignancy within last 5 year , except squamous cell carcinoma , basal cell carcinoma skin situ cervical carcinoma active infection clinically significant cardiac disease regular corticosteroid treatment 4 week prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>